Drug interactions
Erdafitinib + Mitomycin
Severity: Moderate
Erdafitinib and Mitomycin: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Erdafitinib inhibits P-glycoprotein and could raise exposure to P-gp substrates. Mitomycin is a possible P-gp substrate, but the clinical relevance is not established.
What this interaction means in plain words
Erdafitinib and Mitomycin can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Erdafitinib belongs to Oncology; Mitomycin belongs to Oncology.
Why it happens
Inhibition of P-glycoprotein efflux by erdafitinib, potentially increasing mitomycin exposure.
What to do
Monitor for enhanced mitomycin toxicity, particularly myelosuppression and renal effects.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Erdafitinib and Mitomycin, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Mitomycin
- Bacitracin + Mitomycin Major
- Deferiprone + Mitomycin Major
- Dengue vaccine + Mitomycin Major
- Etrasimod + Mitomycin Major
- Fingolimod + Mitomycin Major
- Mitomycin + Palifermin Major
Other interactions of Erdafitinib
Frequently asked questions
Can I take Erdafitinib with Mitomycin?
MediHelp rates the interaction as moderate. Erdafitinib and Mitomycin can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Erdafitinib inhibits P-glycoprotein and could raise exposure to P-gp substrates. Mitomycin is a possible P-gp substrate, but the clinical relevance is not established.
How serious is the interaction between Erdafitinib and Mitomycin?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor for enhanced mitomycin toxicity, particularly myelosuppression and renal effects.
What other medicines interact with Mitomycin?
MediHelp also lists interactions of Mitomycin with, for example, Bacitracin, Deferiprone, Dengue vaccine. The full list is on the Mitomycin page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
